Increase of Adverse Events After Intravenous Injection of Gentamicin in Horses Between 2015 and 2017-From Marketing Authorization Holder's Point of View.
Authors: Stammwitz Viola, Honnens Änne, Hochhuth Dieter, Schuberth Hans-Joachim
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Between 2015 and 2017, a dramatic rise in anaphylactic-like reactions following intravenous gentamicin administration prompted a comprehensive investigation that revealed histamine contamination in the active pharmaceutical ingredient—a finding that ultimately affected both veterinary and human medicine globally. Researchers from a German Marketing Authorization Holder analysed pharmacovigilance data and worked alongside API manufacturers and regulatory authorities to trace the contamination source and implement corrective measures across the supply chain. The horses presenting with adverse reactions served as an early warning system for a human health threat that may otherwise have gone undetected, highlighting how closely the safety profiles of fermentative antibiotics in veterinary and human use are interconnected. Beyond the immediate clinical implications for practitioners administering gentamicin, this incident underscores the critical value of spontaneous adverse event reporting in identifying systemic manufacturing or formulation problems that laboratory testing alone might miss. For equine professionals, the case exemplifies why meticulous documentation of drug reactions—however subtle—remains essential to triggering the investigations that protect both animal and public health.
Read the full abstract on PubMed
Practical Takeaways
- •Clinicians should report all adverse reactions to intravenous gentamicin (and other fermentation-derived APIs) through pharmacovigilance systems, as equine cases can signal serious human health risks
- •Consider alternative aminoglycosides or antimicrobials when gentamicin has been associated with anaphylactic reactions in your region, and verify product batch/source safety
- •Understanding that contamination in fermentation-derived pharmaceutical ingredients is possible helps practitioners recognize unusual adverse event clusters as potential manufacturing issues rather than patient-specific reactions
Key Findings
- •Between 2015 and 2017, a marked increase in anaphylactic-like reactions occurred following intravenous gentamicin administration in horses and humans worldwide
- •Histamine contamination of the gentamicin active pharmaceutical ingredient was identified as the root cause of the adverse events
- •The veterinary observations in horses served as an early warning indicator for a broader human health safety threat
- •Improved safety measures and pharmacovigilance protocols were implemented across both veterinary and human medicinal product regulations